{"id":194,"date":"2017-03-13T16:27:42","date_gmt":"2017-03-13T07:27:42","guid":{"rendered":"http:\/\/www2.med.osaka-u.ac.jp\/wwwmed\/eng\/activities\/research\/joint\/department-of-immunology-and-regenerative-medicine"},"modified":"2023-12-12T13:40:23","modified_gmt":"2023-12-12T04:40:23","slug":"immunology","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/eng\/introduction\/research\/joint\/immunology","title":{"rendered":"Immunology and Regenerative Medicine"},"content":{"rendered":"<ul class=\"linkBar clearfix\"><!-- <!-- \n\n<li><a href=\"#\" target=\"_blank\" rel=\"noopener\">Website<\/a><\/li>\n\n --><\/p>\n<li><a href=\"https:\/\/www.med.osaka-u.ac.jp\/introduction\/research-2\/joint\/immunology\">Text in Japanese<\/a><\/li>\n<p><!-- <!-- \n\n<li><a href=\"#\" target=\"_blank\" class=\"pdf\" rel=\"noopener\">\u5927\u5b66\u9662\u751f\u5411\u3051\u7814\u7a76\u6982\u8981<\/a><\/li>\n\n --><\/ul>\n<div class=\"index\">\n<div class=\"title\">Cancer immunotherapies<\/div>\n<ul>\n<li>New culture technologies for lymphocytes in cancer immunotherapies<\/li>\n<li>New screeing technologies for chimeric antigen receptors (CAR)<\/li>\n<\/ul>\n<\/div>\n<h4>Immunotherapy technologies for controlling the immune system with high quality control<\/h4>\n<p>We have developed a method that modifies glycosylation levels for the quality control of immune cells towards future cancer immunotherapies. Specifically, we are modifying the glycosylation of activated T cells. When introducing a chimeric antigen receptor (CAR) to patient T cells, both the quality of the CAR and the T cell activity are essential. Therefore, we are developing screening methods for high CAR quality. Using this screening technology with glycosylation-modified T cells, we aim to develop an immunotherapy applicable to cancer treatment.<\/p>\n<p>&nbsp;<\/p>\n<p class=\"figure\"><a href=\"http:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/\/activities\/results\/2017\/result_2017_article_02_01.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-4889 size-full\" src=\"http:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2019\/05\/e286074e12d65efe9e7b348e5f2ca2fc.jpg?_t=1559018068\" alt=\"\" width=\"960\" height=\"720\" srcset=\"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2019\/05\/e286074e12d65efe9e7b348e5f2ca2fc.jpg 960w, https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2019\/05\/e286074e12d65efe9e7b348e5f2ca2fc-400x300.jpg 400w, https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-content\/uploads\/2019\/05\/e286074e12d65efe9e7b348e5f2ca2fc-768x576.jpg 768w\" sizes=\"(max-width: 960px) 100vw, 960px\" \/><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Text in Japanese Cancer immunotherapies New culture technologies for lymphocytes in cancer immunotherapies New [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":91,"menu_order":168,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/194"}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/comments?post=194"}],"version-history":[{"count":12,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/194\/revisions"}],"predecessor-version":[{"id":8095,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/194\/revisions\/8095"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/pages\/91"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/eng\/wp-json\/wp\/v2\/media?parent=194"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}